Tests efruxifermin in adults with cirrhosis caused by fatty liver disease
Tests efruxifermin against a placebo in adults with cirrhosis from MASH.
Plain-language title generated from the registry record
Registry title: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Key facts
- Where
- Bunkyō-Ku, Fukui-shi, Kyoto, Maebashi, Minato-Ku, Musashino, Ōgaki, Shinjuku, Suita-shi, Wakayama, and Yokohama, JapanSee the 11 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06528314, who can take part
Where in Japan
- Bunkyō-KuBunkyō-Ku, JapanTaking people
- Fukui-shiFukui-shi, JapanTaking people
- KyotoKyoto, JapanTaking people
- MaebashiMaebashi, JapanTaking people
- Minato-KuMinato-Ku, JapanTaking people
- MusashinoMusashino, JapanTaking people
- ŌgakiŌgaki, JapanTaking people
- ShinjukuShinjuku, JapanTaking people
- Suita-shiSuita-shi, JapanTaking people
- WakayamaWakayama, JapanTaking people
- YokohamaYokohama, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Akero Therapeutics, Inc
- Trial code
- NCT06528314
- Record updated
- 13 October 2026
- Original description
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Inclusion: Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of >=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities; Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.
Exclusion: Any current or prior history of decompensated liver disease; Other inclusion and exclusion criteria may apply; Type 1 diabetes or unstable Type 2 diabetes; Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.